Integrin-linked kinase (ILK) in hematologic malignancies: Bridging molecular mechanisms to therapeutic innovation
BioImpacts · 29.04.2026 · 16 · 32638
DOI: 10.34172/bi.32638 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BioImpacts, online erschienen am 29.04.2026. Verfasst von Omer Qutaiba B Allela und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Alnoor University, Mosul, Iraq. Die Arbeit nennt 208 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Therapy resistance remains a formidable challenge in hematologic malignancies despite significant advances in targeted therapies. This comprehensive review examines integrin-linked kinase (ILK) as a critical molecular hub at the nexus of cell adhesion, signal transduction, and therapy resistance across leukemias, lymphomas, and multiple myeloma. Unlike in solid tumors, where ILK primarily drives invasion and metastasis, in hematologic malignancies it uniquely mediates microenvironmental protection and therapy resistance through distinct signaling networks. ILK functions as a central mediator connecting microenvironmental signals to intracellular survival pathways, with expression levels 5-20-fold higher in malignant cells compared to normal counterparts. Through systematic analysis of structural properties, expression patterns, downstream signaling, and microenvironmental interactions, we present compelling evidence for ILK as a promising therapeutic target capable of overcoming resistance mechanisms. Current data demonstrate that ILK inhibition simultaneously disrupts multiple survival pathways, sensitizes resistant cells to established therapies, and selectively targets therapy-resistant leukemic stem cells while sparing normal progenitors. This review provides a comprehensive framework for translating ILK-targeted approaches into innovative therapeutic strategies with significant potential to improve outcomes in treatment-refractory hematologic malignancies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy, Alnoor University, Mosul, Iraq.
- Ahl al bayt University, Kerbala, Iraq.
- Marwadi University Research Center, Department of Pharmaceutical Sciences, Faculty of Health Sciences, Marwadi University, Rajkot, Gujarat, India.
- Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
- Department of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha-751030, India.
- Department of Pharmacy, Graphic Era Hill University, Dehradun, India.
ORCID-Profile: Omer Qutaiba B Allela
Zitieren
APA
B Allela, O. Q., Shareef, A., Kyada, A., Malathi, H., Maharana, L., Puri, D., Gupta, H., Polatova, D., Sameer, H. N., Yaseen, A., H Athab, Z., & Adil, M. (2026). Integrin-linked kinase (ILK) in hematologic malignancies: Bridging molecular mechanisms to therapeutic innovation. BioImpacts, 16, 32638. https://doi.org/10.34172/bi.32638
Vancouver
B Allela OQ, Shareef A, Kyada A, Malathi H, Maharana L, Puri D, et al. Integrin-linked kinase (ILK) in hematologic malignancies: Bridging molecular mechanisms to therapeutic innovation. BioImpacts. 2026;16:32638. doi:10.34172/bi.32638
BibTeX
@article{BAllela2026,
author = {B Allela, Omer Qutaiba and Shareef, Abdulkareem and Kyada, Ashishkumar and Malathi, H and Maharana, Laxmidhar and Puri, Dinesh and Gupta, Harshit and Polatova, Djamila and Sameer, Hayder Naji and Yaseen, Ahmed and H Athab, Zainab and Adil, Mohaned},
title = {Integrin-linked kinase (ILK) in hematologic malignancies: Bridging molecular mechanisms to therapeutic innovation},
journal = {BioImpacts},
year = {2026},
volume = {16},
pages = {32638},
doi = {10.34172/bi.32638}
}
EUVIMED